| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2008PNAS..10517961M |
| P356 | DOI | 10.1073/PNAS.0809957105 |
| P932 | PMC publication ID | 2582212 |
| P698 | PubMed publication ID | 19004807 |
| P5875 | ResearchGate publication ID | 23469249 |
| P50 | author | Suzanne Cory | Q1231087 |
| Andrew W. Roberts | Q43445505 | ||
| Kylie D. Mason | Q46040354 | ||
| David C Huang | Q56987660 | ||
| Andrew Wei | Q88259292 | ||
| Clare L Scott | Q88796492 | ||
| P2093 | author name string | Cassandra J Vandenberg | |
| P2860 | cites work | PUMA induces the rapid apoptosis of colorectal cancer cells | Q24291462 |
| PUMA, a novel proapoptotic gene, is induced by p53 | Q24291463 | ||
| Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function | Q24293924 | ||
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
| Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes | Q24651802 | ||
| Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis | Q28144256 | ||
| Myc pathways provoking cell suicide and cancer | Q28190322 | ||
| The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Live or let die: the cell's response to p53 | Q29547663 | ||
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 | ||
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Q33266778 | ||
| Burkitt's lymphoma: molecular pathogenesis and treatment | Q33989044 | ||
| Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation | Q34245495 | ||
| Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantat | Q34734892 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival | Q35904282 | ||
| The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells | Q36354457 | ||
| Activation of cellular oncogenes in hemopoietic cells by chromosome translocation | Q39591625 | ||
| Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program | Q40034582 | ||
| Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. | Q40126446 | ||
| Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. | Q40174205 | ||
| Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas | Q40234300 | ||
| Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. | Q40479135 | ||
| Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. | Q41714456 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Genetic analysis of chemoresistance in primary murine lymphomas. | Q43422059 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Molecular diagnosis of Burkitt's lymphoma | Q45207362 | ||
| A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling | Q51940347 | ||
| A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma | Q53595735 | ||
| The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice | Q57338722 | ||
| Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo | Q73893207 | ||
| Antiapoptotic BCL-2 is required for maintenance of a model leukemia | Q80591496 | ||
| P433 | issue | 46 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 17961-17966 | |
| P577 | publication date | 2008-11-11 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas | |
| P478 | volume | 105 |
| Q53090926 | 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients |
| Q38640917 | ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development |
| Q33405436 | ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia |
| Q50018704 | Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells |
| Q35088734 | Apoptotic cell signaling in cancer progression and therapy |
| Q35212727 | Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. |
| Q37235693 | BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells |
| Q42177793 | BCL-W has a fundamental role in B cell survival and lymphomagenesis |
| Q53003244 | BCL2 inhibition in double hit lymphoma. |
| Q38779981 | BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. |
| Q24305138 | BH3 domains other than Bim and Bid can directly activate Bax/Bak |
| Q39832798 | BH3-mimetics--the solution to chemoresistance? |
| Q36057611 | Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells |
| Q42335354 | CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. |
| Q91260479 | Characterization of a novel human BFL-1-specific monoclonal antibody |
| Q41339798 | Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy |
| Q35128216 | Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma |
| Q36471376 | Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. |
| Q38793940 | Comparison of in vitro antileukemic activity of obatoclax and ABT-737. |
| Q36267666 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone |
| Q38172752 | Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. |
| Q35493953 | Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity |
| Q26770385 | Current challenges and novel treatment strategies in double hit lymphomas |
| Q37921609 | Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases |
| Q90448064 | Effects of ABT-737 combined with irradiation treatment on uterine cervical cancer cells |
| Q34369809 | Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance |
| Q38650669 | Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. |
| Q84218211 | From molecules and cells to diseases: West meets East for medical research in Tianjin |
| Q64054212 | IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis |
| Q37330840 | Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice. |
| Q37347239 | Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma |
| Q35594851 | Intracellular delivery system for antibody-Peptide drug conjugates |
| Q37521403 | Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation |
| Q37351043 | Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival |
| Q37425601 | MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts |
| Q37732974 | MYC in oncogenesis and as a target for cancer therapies |
| Q37142412 | MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma |
| Q38233772 | MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches |
| Q26785379 | MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management |
| Q34450473 | Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim |
| Q37163339 | Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. |
| Q39168078 | Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells |
| Q36668047 | Mitochondrial permeability transition pore as a selective target for anti-cancer therapy |
| Q37269044 | New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008. |
| Q36418000 | Oncogenes in cell survival and cell death |
| Q37115217 | Perforin-mediated suppression of B-cell lymphoma |
| Q35678266 | Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. |
| Q61798926 | Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy |
| Q33438494 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
| Q39413018 | Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. |
| Q36473581 | Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice |
| Q36797266 | RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. |
| Q46029936 | Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent. |
| Q33398808 | Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease |
| Q28476828 | Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma |
| Q39456786 | Targeting BCL-2-like Proteins to Kill Cancer Cells |
| Q38996888 | Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies |
| Q27011870 | Targeting Mcl-1 for the therapy of cancer |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q37488736 | Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 |
| Q51746852 | Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy |
| Q92445776 | The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death |
| Q47166330 | The BCL-2 arbiters of apoptosis and their growing role as cancer targets |
| Q36067778 | The BCL-2 protein family, BH3-mimetics and cancer therapy |
| Q45916401 | The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. |
| Q39662629 | The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib |
| Q30418414 | The Use of Therapeutic Peptides to Target and to Kill Cancer Cells |
| Q39700227 | The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma |
| Q38798849 | To Prime, or Not to Prime: That Is the Question |
| Q42117299 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine |
| Q37431491 | Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics |
| Q98725864 | Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment |
| Q37594415 | Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma |
Search more.